In a filing, Halozyme Therapeutics Inc revealed its Director Connaughton Bernadette unloaded Company’s shares for reported $0.14 million on Jan 05 ’26. In the deal valued at $70.25 per share,2,000 shares were sold. As a result of this transaction, Connaughton Bernadette now holds 40,123 shares worth roughly $2.91 million.
Then, BERNADETTE CONNAUGHTON bought 2,000 shares, generating $140,620 in total proceeds.
Before that, Caudill Cortney sold 4,263 shares. Halozyme Therapeutics Inc shares valued at $277,905 were divested by the SVP, CHIEF OPERATING OFFICER at a price of $65.19 per share. As a result of the transaction, Caudill Cortney now holds 12,737 shares, worth roughly $0.92 million.
Goldman downgraded its Halozyme Therapeutics Inc [HALO] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in mid October from “an Underperform” to “a Market perform”. Morgan Stanley also remained covering HALO and has increased its forecast on August 06, 2025 with a “an Overweight” recommendation from previously “an Equal-weight” rating.
Price Performance Review of HALO
On Monday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock jump 0.47% to $72.47. Over the last five days, the stock has gained 3.07%. Halozyme Therapeutics Inc shares have risen nearly 41.57% since the year began. Nevertheless, the stocks have risen 7.68% over the past one year.
How much short interest is there in Halozyme Therapeutics Inc?
A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2025-12-15, growing by 21447.0 shares to a total of 12.5 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 12.48 million shares. There was a rise of 0.17%, which implies that there is a positive sentiment for the stock.
